Tewodros Eguale1, Robyn Tamblyn, Nancy Winslade, David Buckeridge. 1. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, 1140 Pine Avenue West, Montreal, Quebec, Canada. tewodros.eguale@mail.mcgill.ca
Abstract
BACKGROUND: Current pharmacosurveillance methods do not provide timely information on drug safety and effectiveness. Real-time surveillance using electronic prescribing systems could address this problem; however, the data collected using these systems has not been validated. We investigated the accuracy of using orders for drug discontinuation and dose change in an electronic prescribing system as a potential source of information for drug safety and effectiveness. OBJECTIVES: To determine the accuracy of an electronic prescribing and drug management system in documenting orders for discontinuation and dose changes of prescription drug treatment, and in identifying the reasons for the drug discontinuation and dose change. STUDY DESIGN AND SETTING: We prospectively assessed the accuracy of electronic prescription orders for drug discontinuation and dose change by comparing them with treatment changes documented by physician-facilitated medical chart review (gold standard). Validity was evaluated in 620 patients of 22 community-based primary care physicians in addition to the reasons for these treatment changes. RESULTS: A total of 141 (41.7%) drug discontinuation orders and 197 (58.3%) changes in drug doses were identified by chart review, the majority of which were for cardiovascular and CNS drugs. Ineffective treatment (30.8%), adjusting dose to optimize treatment (25.1%) and adverse drug reactions (21.9%) were the most common reasons for treatment change. The sensitivity of the electronic prescribing system in identifying physician-initiated drug discontinuations and dose changes was 67.0% (95% CI 54.1, 77.7) and the specificity was 99.7% (95% CI 99.5, 99.9). The positive and negative predictive values of electronic treatment discontinuation and change orders were 97.3% (95% CI 95.6, 98.7) and 95.8% (95% CI 92.9, 97.7), respectively. CONCLUSION: An electronic prescribing and drug management system documents drug discontinuation and dose-change orders with high specificity and moderate sensitivity. Ineffective treatment, dose optimization and adverse drug reactions were the most common reasons for drug discontinuation or dose changes. The electronic prescribing system offers a new method for augmenting pharmacosurveillance.
BACKGROUND: Current pharmacosurveillance methods do not provide timely information on drug safety and effectiveness. Real-time surveillance using electronic prescribing systems could address this problem; however, the data collected using these systems has not been validated. We investigated the accuracy of using orders for drug discontinuation and dose change in an electronic prescribing system as a potential source of information for drug safety and effectiveness. OBJECTIVES: To determine the accuracy of an electronic prescribing and drug management system in documenting orders for discontinuation and dose changes of prescription drug treatment, and in identifying the reasons for the drug discontinuation and dose change. STUDY DESIGN AND SETTING: We prospectively assessed the accuracy of electronic prescription orders for drug discontinuation and dose change by comparing them with treatment changes documented by physician-facilitated medical chart review (gold standard). Validity was evaluated in 620 patients of 22 community-based primary care physicians in addition to the reasons for these treatment changes. RESULTS: A total of 141 (41.7%) drug discontinuation orders and 197 (58.3%) changes in drug doses were identified by chart review, the majority of which were for cardiovascular and CNS drugs. Ineffective treatment (30.8%), adjusting dose to optimize treatment (25.1%) and adverse drug reactions (21.9%) were the most common reasons for treatment change. The sensitivity of the electronic prescribing system in identifying physician-initiated drug discontinuations and dose changes was 67.0% (95% CI 54.1, 77.7) and the specificity was 99.7% (95% CI 99.5, 99.9). The positive and negative predictive values of electronic treatment discontinuation and change orders were 97.3% (95% CI 95.6, 98.7) and 95.8% (95% CI 92.9, 97.7), respectively. CONCLUSION: An electronic prescribing and drug management system documents drug discontinuation and dose-change orders with high specificity and moderate sensitivity. Ineffective treatment, dose optimization and adverse drug reactions were the most common reasons for drug discontinuation or dose changes. The electronic prescribing system offers a new method for augmenting pharmacosurveillance.
Authors: Robyn Tamblyn; Allen Huang; Yuko Kawasumi; Gillian Bartlett; Roland Grad; André Jacques; Martin Dawes; Michal Abrahamowicz; Robert Perreault; Laurel Taylor; Nancy Winslade; Lise Poissant; Alain Pinsonneault Journal: J Am Med Inform Assoc Date: 2005-12-15 Impact factor: 4.497
Authors: Douglas S Bell; Richard S Marken; Robin C Meili; C Jason Wang; Mayde Rosen; Robert H Brook Journal: Health Aff (Millwood) Date: 2004 Jan-Jun Impact factor: 6.301
Authors: Carolien M J van der Linden; Paul A F Jansen; Rob J van Marum; René J E Grouls; Toine C G Egberts; Erik H M Korsten Journal: Drugs Aging Date: 2012-12 Impact factor: 3.923
Authors: Geneviève Cadieux; David L Buckeridge; André Jacques; Michael Libman; Nandini Dendukuri; Robyn Tamblyn Journal: BMC Public Health Date: 2011-01-07 Impact factor: 3.295
Authors: Klaas A Hartholt; Nathalie van der Velde; Caspar W N Looman; Martien J M Panneman; Ed F van Beeck; Peter Patka; Tischa J M van der Cammen Journal: PLoS One Date: 2010-11-12 Impact factor: 3.240
Authors: Alan J Forster; Tobias E Erlanger; Alison Jennings; Claudine Auger; David Buckeridge; Carl van Walraven; Robyn Tamblyn Journal: Trials Date: 2015-01-08 Impact factor: 2.279
Authors: Robyn Tamblyn; Allen R Huang; Ari N Meguerditchian; Nancy E Winslade; Christian Rochefort; Alan Forster; Tewodros Eguale; David Buckeridge; André Jacques; Kiyuri Naicker; Kristen E Reidel Journal: Trials Date: 2012-08-27 Impact factor: 2.279